Insider Buying: Medicenna Therapeutics (TSE:MDNA) Insider Acquires 10,000 Shares of Stock
I'm PortAI, I can summarize articles.
Medicenna Therapeutics insider David Hyman purchased 10,000 shares at C$1.12 each, totaling C$11,200, increasing his stake by 25% to 50,000 shares. The company's stock traded at C$1.09 with a market cap of C$90.92 million. Medicenna, a Canadian immuno-oncology firm, focuses on developing cancer treatments. Despite a negative net margin and return on equity, analysts expect a -0.37 EPS for the year. The stock has a Hold rating, with analysts favoring other stocks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments